Yoshiaki Sagara

863 citations

31 papers · 639 indexed · h-index 14

Impact in

Cancer Research top 10%
- Breast Cancer Treatment Studies
Oncology top 10%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology

Papers in

Cancer Research 11
- Breast Cancer Treatment Studies 7
Oncology 17
- Cancer Treatment and Pharmacology 8
- HER2/EGFR in Cancer Research 7
- Cancer Cells and Metastasis 5

Co-authors: Yasuyo Ohi Yasuaki Sagara Yoshiaki Rai Yoshiatsu Sagara Yoshihisa Umekita Akihide Tanimoto Masakazu Souda Daisuke Yotsumoto
Journals: Breast Cancer (6 papers)Breast Cancer Research and Treatment (3 papers)Histopathology (2 papers)Diagnostic Pathology (2 papers)British Journal of Cancer (1 paper)
Partner nations: Japan United States Switzerland

In The Last Decade

Yoshiaki Sagara

29 papers receiving 622 citations

Peers

Countries citing papers authored by Yoshiaki Sagara

Since Specialization

Citations

This map shows the geographic impact of Yoshiaki Sagara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiaki Sagara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiaki Sagara more than expected).

Fields of papers citing papers by Yoshiaki Sagara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiaki Sagara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiaki Sagara. The network helps show where Yoshiaki Sagara may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yoshiaki Sagara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yoshiaki Sagara Line = papers co-authored together Yoshiaki Sagara links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes Clinical Breast Cancer ·Reiki Nishimura, M K Ranade, Tetsuhiko Taira, Toshiko Miyaki, II Sun Kim, Daisuke Yotsumoto, 林颐, Harold Van Der Werff, Hanne Seelbacher-Holzmann, Aqila Salmaagista, Shinichi Baba, Yasuyo Ohi, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara	2024	2
2	Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer Breast Cancer ·M K Ranade, Masahiro Kashiwaba, Urvashi Andotra, Harold Van Der Werff, 林颐, II Sun Kim, Yoshiaki Rai, Tetsuhiko Taira, Yoshiaki Sagara, Yasuyo Ohi, 洋一森口, Young-Won Lee, Sae Byul Lee, Gyungyub Gong, Young Kee Shin, Mi Kwon, Yasuaki Sagara	2023	1
3	Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis Cancers ·Sophie A. Leheny, Ионова Валентина Даниловна, Tomofumi Hamada, Seiya Yokoyama, Lerong Qin, 義近大谷, Mahiro Beppu, Yasuaki Sagara, Yoshiaki Sagara, Tsuyoshi Sugiura	2021	27
4	Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer British Journal of Cancer ·Hirofumi Mukai, Yukari Uemura, Hiromitsu Akabane, Takanori Watanabe, Young‐Jin Park, Masato Takahashi, Yoshiaki Sagara, Reiki Nishimura, Tsutomu Takashima, Tomomi Fujisawa, Yasuo Hozumi, Takuya Kawahara	2021	11
5	Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer Anticancer Research ·Toshihiro Tanaka, Maki Tanaka, Hidemi Furusawa, Yoshihiko Kamada, Yoshiaki Sagara, Keisei Anan, Huang Zheng-Yang, G Scharf, Marina Sanches Oliveira, Kazuo Tamura, Shoshu Mitsuyama, (unknown)	2020	2
6	Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer Breast Cancer Research and Treatment ·Akira I. Hida, Takahiro Watanabe, Yasuaki Sagara, Masahiro Kashiwaba, Yoshiaki Sagara, Kenjiro Aogi, Yasuyo Ohi, Akihide Tanimoto	2019	33
7	Correlation between 18F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer European Journal of Radiology ·Lara Martin, Mitsuhiro Tozaki, Michiro Sasaki, Akira I. Hida, Yasuyo Ohi, Kazunori Kubota, Yoshiaki Sagara	2019	32
8	Does integrated shimming improve lesion detection in whole-body diffusion-weighted examinations of patients with breast cancer? Japanese Journal of Radiology ·Michiro Sasaki, Mitsuhiro Tozaki, Katsuya Maruyama, Thomas Benkert, Lara Martin, Daisuke Yotsumoto, Linda Loubser, Yoshiaki Sagara	2018	4
9	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer Breast Cancer Research and Treatment ·Hiroji Iwata, Norikazu Masuda, Daigo Yamamoto, Yoshiaki Sagara, Nobuaki Sato, Yutaka Yamamoto, Mitsue Saito, Takashi Fujita, Shoji Oura, Junichiro Watanabe, Fadumo Mohamed Jaylani, BU QIAN WANG, Satoshi Hattori, Wang Jia-li, Katsumasa Kuroi	2017	10
10	Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial BMC Cancer ·Takeru Shiroiwa, Takashi Fukuda, Kojiro Shimozuma, Annie Labourie-Racapé, Yasuhiro Hagiwara, Takuya Kawahara, Shozo Ohsumi, Yasuo Hozumi, Yoshiaki Sagara, Yasuo Ohashi, Hirofumi Mukai	2017	1
11	Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values Japanese Journal of Radiology ·Michiro Sasaki, Mitsuhiro Tozaki, Kazunori Kubota, Lara Martin, Daisuke Yotsumoto, Yasuaki Sagara, Yasuyo Ohi, Linda Loubser, Yoshiaki Sagara	2017	13
12	Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies Breast Cancer Research and Treatment ·Akira I. Hida, Yasuaki Sagara, Daisuke Yotsumoto, Shuichi Kanemitsu, Harold Van Der Werff, Shinichi Baba, Yoshiaki Rai, Yumi Oshiro, Kenjiro Aogi, Yoshiaki Sagara, Yasuyo Ohi	2016	50
13	Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial The Lancet Oncology ·Tsutomu Takashima, Hirofumi Mukai, Fumikata Hara, Nobuaki Matsubara, Tsuyoshi Saito, Toshimi Takano, Young‐Jin Park, Tatsuya Toyama, Yasuo Hozumi, Junji Tsurutani, Shigeru Imoto, Takanori Watanabe, Yoshiaki Sagara, Reiki Nishimura, Kojiro Shimozuma, Yasuo Ohashi	2015	66
14	Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer Diagnostic Pathology ·Yoshihisa Umekita, Yasuyo Ohi, Masakazu Souda, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara, Shugo Tamada, Akihide Tanimoto	2011	25
15	Mucocele-like lesions of the breast: a long-term follow-up study Diagnostic Pathology ·Yasuyo Ohi, Yoshihisa Umekita, Yoshiaki Rai, Yasuaki Sagara, Shinichi Baba, Shugo Tamada, Yoshiaki Sagara, Samir A. El-Tantawy, Takako Yoshioka, Kazuhito Hatanaka, Yoshiatsu Sagara, Akihide Tanimoto	2011	12
16	Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer Histopathology ·Yasuyo Ohi, Yoshihisa Umekita, Takako Yoshioka, Masakazu Souda, Yoshiaki Rai, Yoshiaki Sagara, Yasuaki Sagara, Yoshiatsu Sagara, Akihide Tanimoto	2011	77
17	Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node‐positive breast cancers: a long‐term follow‐up study Histopathology ·Takako Yoshioka, Yoshihisa Umekita, Yasuyo Ohi, Masakazu Souda, Yoshiatsu Sagara, Yasuaki Sagara, Yoshiaki Sagara, Yoshiaki Rai, Akihide Tanimoto	2011	47
18	The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype Cancer Chemotherapy and Pharmacology ·Kenjiro Aogi, Masayuki Yoshida, Yoshiaki Sagara, Shunji Kamigaki, M. Okazaki, Jumpei Funai, Toshio Fujimoto, Masakazu Toi, Toshiaki Saeki, Shigemitsu Takashima	2010	9
19	Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening) ·Yoshiaki Rai, Yasuaki Sagara, M. Zunaid, Samir A. El-Tantawy, M. Rohani-Rad, Yoshiaki Sagara, P R Woodfield, Shinichi Baba, Y Matsuyama, Ilias Cheimariotis, Yoshiatsu Sagara	2008	0
20	Clear cell hidradenoma of the breast: a case report with review of the literature Breast Cancer ·Yasuyo Ohi, Yoshihisa Umekita, Yoshiaki Rai, Samir A. El-Tantawy, Yoshiaki Sagara, Yasuaki Sagara, P.T.S. Sandon, Erica A. Milkovich, Shinta Dwi Kusniawati, Aichi Yoshida, Hiroki Yoshida	2007	23

About Yoshiaki Sagara

Yoshiaki Sagara is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Dermatology and Radiology, Nuclear Medicine and Imaging, having authored 31 papers that have together received 639 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (7 papers), HER2/EGFR in Cancer Research (7 papers), Breast Lesions and Carcinomas (7 papers), Cancer Cells and Metastasis (5 papers), MRI in cancer diagnosis (4 papers), Radiomics and Machine Learning in Medical Imaging (3 papers) and Advanced Breast Cancer Therapies (3 papers). The work is most often cited by research in Cancer Research (221 citations), Oncology (356 citations), Health Informatics (15 citations), Radiology, Nuclear Medicine and Imaging (140 citations) and Dermatology (49 citations). Yoshiaki Sagara has collaborated with scholars based in Japan, United States and Switzerland. Frequent co-authors include Yasuyo Ohi, Yasuaki Sagara, Yoshiaki Rai, Yoshiatsu Sagara, Yoshihisa Umekita, Akihide Tanimoto, Masakazu Souda, Daisuke Yotsumoto, Takako Yoshioka and Akira I. Hida. Their work appears in journals such as Breast Cancer, Breast Cancer Research and Treatment, Histopathology, Diagnostic Pathology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact